Feature Selection with Integrated Gaussian Seahorse Optimization Data Mining for Cross-border Business Cooperation between the Malaysian Medical Industry and Tourism Industry

The cross-border collaboration between the medical industry and the tourism industry has gained significant attention as a promising avenue for economic growth and development. Data mining techniques are employed to extract valuable patterns and insights from large-scale datasets, shedding light on the opportunities and challenges associated with this collaborative effort. This study proposes an integrated approach that combines feature selection with Gaussian Seahorse Optimization Data Mining (GSH-DM) to identify the most relevant features and optimize the data mining process. The GSH-DM assembling comprehensive datasets encompassing information from both the Malaysian medical industry and tourism industry. The integrated GSH-DM model then applies the Gaussian Seahorse Optimization algorithm to optimize the data mining process, enhancing the accuracy and efficiency of pattern discovery. the GSH-DM model, this study aims to uncover hidden patterns, relationships, and predictive models that can guide decision-making and strategy development for cross-border business cooperation. The findings of this study contribute to a deeper understanding of the factors that influence cross-border business cooperation between the Malaysian medical industry and the tourism industry. The integrated GSH-DM approach showcases the potential of combining feature selection techniques with advanced optimization algorithms in data mining applications. The results of GSH-DM provide actionable insights for stakeholders, enabling them to make informed decisions and foster successful cross-border collaborations between the Malaysian medical industry and the tourism industry. The analysis of the results demonstrated that GSH-DM exhibits improved performance for feature selection and classification

Forecasting the demand for medical tourism in different cities of Malaysia

Tourism, combined with the articulation medical, is apparently one more sort of tourism which has acquired massive acclaim in continuous numerous years. In any case, different compositions open with regards to the tourism business and the earnestness of the destinationbe that as it may, the significant viewpoints which determine the fulfillment of medical travelers are not really centered explicitly around Malaysia. There is an absence of exact proof in this space of study which should be connected. Consequently, this study pointed toward investigating the different elements assisting in the development of medical tourism in Malaysia Because the purpose of the study was to find several elements that contribute to the improvement of medical tourism in Malaysia, the data was examined using Structural Equation demonstrating (SEM). Medical travellers who came to Malaysia with the primary intention of looking for medical frameworks other than touring were the authentic people for this study. During the months of December 2012 and February 2013, a total of 266 models were constructed using non-probability judgement inspection. The findings show that destination reality and organisation quality have a significant role in the medical traveler's decision to visit Malaysia for medical tourism

Effect of HIV-1 Infection on Angiopoietin 1 and 2 Levels and Measures of Microvascular and Macrovascular Endothelial Dysfunction.

Background Individuals infected with HIV have an increased risk of developing cardiovascular disease; yet, the underlying mechanisms remain unknown. Recent evidence has implicated the Tie-2 tyrosine kinase receptor system and its associated ligands ANG1 (angiopoietin 1) and ANG2 (angiopoietin 2) in maintaining vascular homeostasis. In the general population, lower ANG1 levels and higher ANG2 levels are strongly correlated with the development of cardiovascular disease. In this study, we aim to investigate the associations of HIV infection with angiopoietin levels and endothelial dysfunction. Methods and Results In this cross-sectional study, we compared measures of ANG1, ANG2, and endothelial dysfunction using flow-mediated vasodilation of the brachial artery in 39 untreated subjects infected with HIV, 47 treated subjects infected with HIV, and 46 uninfected subjects from the SCOPE (Observational Study of the Consequences of the Protease Inhibitor Era) cohort. Compared with uninfected controls, treated individuals infected with HIV had 53.1% lower mean ANG1 levels (P<0.01) and similar ANG2 levels. On the other hand, untreated individuals infected with HIV had similar ANG1 levels, and 29.2% had higher ANG2 levels (P<0.01) compared with uninfected controls. When compared with individuals with untreated HIV infection, those with treated HIV infection had 56% lower ANG1 levels (P<0.01) and 22% lower ANG2 levels (P<0.01).Both treated and untreated HIV infection were associated with significant impairment in hyperemic velocity, a key measure of microvascular dysfunction (median 61 versus 72 cm/s, P<0.01), compared with uninfected controls (median 73 cm/s). This difference persisted after adjustment for ANG1 and ANG2 levels. Interestingly, when compared with untreated individuals infected with HIV, treated individuals infected with HIV had worse hyperemic velocity (-12.35 cm/s, P=0.05). In contrast, HIV status, ANG1 levels, and ANG2 levels were not associated with macrovascular dysfunction as measured by flow-mediated dilatation and brachial artery diameter, 2 other measures of vascular homeostasis. Conclusions HIV infection affects the balance between levels of ANG1 and ANG2 and may disturb endothelial homeostasis through disruption of vascular homeostasis. Individuals with treated HIV had decreased ANG1 levels and similar ANG2 levels, whereas individuals with untreated HIV had similar ANG1 levels and increased ANG2 levels, suggesting that treatment status may alter the balance between ANG1 and ANG2. HIV also promotes endothelial dysfunction via impairment of microvascular dysfunction, independent of the Tie-2 receptor system; the finding of worse microvascular dysfunction in the setting of treated HIV infection may reflect the impact of viral persistence on the microvasculature or toxicities of specific antiretroviral regimens. Further research to clarify the mechanism of HIV-mediated endothelial dysfunction is necessary to advance treatment of cardiovascular complications of HIV infection

The immunologic effects of mesalamine in treated HIV-infected individuals with incomplete CD4+ T cell recovery: a randomized crossover trial.

The anti-inflammatory agent, mesalamine (5-aminosalicylic acid) has been shown to decrease mucosal inflammation in ulcerative colitis. The effect of mesalamine in HIV-infected individuals, who exhibit abnormal mucosal immune activation and microbial translocation (MT), has not been established in a placebo-controlled trial. We randomized 33 HIV-infected subjects with CD4 counts <350 cells/mm3 and plasma HIV RNA levels <40 copies/ml on antiretroviral therapy (ART) to add mesalamine vs. placebo to their existing regimen for 12 weeks followed by a 12 week crossover to the other arm. Compared to placebo-treated subjects, mesalamine-treated subjects did not experience any significant change in the percent CD38+HLA-DR+ peripheral blood CD4+ and CD8+ T cells at week 12 (P = 0.38 and P = 0.63, respectively), or in the CD4+ T cell count at week 12 (P = 0.83). The percent CD38+HLA-DR+ CD4+ and CD8+ T cells also did not change significantly in rectal tissue (P = 0.86, P = 0.84, respectively). During the period of mesalamine administration, plasma sCD14, IL-6, D-dimer, and kynurenine to tryptophan ratio were not changed significantly at week 12 and were similarly unchanged at week 24. This study suggests that, at least under the conditions studied, the persistent immune activation associated with HIV infection is not impacted by the anti-inflammatory effects of mesalamine.ClinicalTrials.gov NCT01090102

Baseline Characteristics.

<p>ART, antiretroviral therapy; NRTI, nucleoside reverse transcriptase inhibitors; NNRTI, non-nucleoside reverse transcriptase inhibitors; PI, protease inhibitor; INSTI, integrase strand transfer inhibitor; AST, aspartate transaminase; ALT, alanine transaminase.</p><p>Baseline Characteristics.</p

Changes in immunologic, virologic, and cardiovascular parameters during the first 12 weeks of study.

<p>FMD, flow-mediated vasodilation of the brachial artery; K:T, kynurenine:tryptophan; VTI, velocity time integral.</p>a<p>There were 15 and 11 consented to mucosal biopsies in the placebo arm and mesalamine arm, respectively, but one in each arm did not contribute a second time point.</p>b<p>Total HIV RNA and DNA level from whole GALT biopsies were based on cell equivalents normalized by GAPDH and TERT copy number, respectively.</p><p>Changes in immunologic, virologic, and cardiovascular parameters during the first 12 weeks of study.</p

Enrollment, allocation, and follow-up for trial subjects.

<p>The outcomes of the 41 screened subjects are described in the flow diagram.</p

Changes in immunologic, virologic, and cardiovascular parameters during 12 weeks after treatment crossover.

<p>Changes in immunologic, virologic, and cardiovascular parameters during 12 weeks after treatment crossover.</p

Changes in T cell activation and soluble markers aggregating the 12 weeks on mesalamine.

<p>Changes in T cell activation and soluble markers aggregating the 12 weeks on mesalamine.</p

The Immunologic Effects of Mesalamine in Treated HIV-Infected Individuals with Incomplete CD4+ T Cell Recovery: A Randomized Crossover Trial

<div><p>The anti-inflammatory agent, mesalamine (5-aminosalicylic acid) has been shown to decrease mucosal inflammation in ulcerative colitis. The effect of mesalamine in HIV-infected individuals, who exhibit abnormal mucosal immune activation and microbial translocation (MT), has not been established in a placebo-controlled trial. We randomized 33 HIV-infected subjects with CD4 counts <350 cells/mm³ and plasma HIV RNA levels <40 copies/ml on antiretroviral therapy (ART) to add mesalamine vs. placebo to their existing regimen for 12 weeks followed by a 12 week crossover to the other arm. Compared to placebo-treated subjects, mesalamine-treated subjects did not experience any significant change in the percent CD38+HLA-DR+ peripheral blood CD4+ and CD8+ T cells at week 12 (P  = 0.38 and P  = 0.63, respectively), or in the CD4+ T cell count at week 12 (P  = 0.83). The percent CD38+HLA-DR+ CD4+ and CD8+ T cells also did not change significantly in rectal tissue (P  = 0.86, P  = 0.84, respectively). During the period of mesalamine administration, plasma sCD14, IL-6, D-dimer, and kynurenine to tryptophan ratio were not changed significantly at week 12 and were similarly unchanged at week 24. This study suggests that, at least under the conditions studied, the persistent immune activation associated with HIV infection is not impacted by the anti-inflammatory effects of mesalamine.</p><p>Trial Registration</p><p>ClinicalTrials.gov <a href="https://clinicaltrials.gov/ct2/show/NCT01090102?term=mesalamine+hiv&rank=1" target="_blank">NCT01090102</a></p></div